Obecabtagene Autoleucel
Brand names: Aucatzyl · Active ingredient: Obecabtagene Autoleucel
In short: AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
What is Obecabtagene Autoleucel used for?
AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
âš Boxed warning (FDA's strongest warning)
Cytokine Release Syndrome (CRS) occurred in patients receiving AUCATZYL. Do not administer AUCATZYL to patients with active infection or inflammatory disorders. Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS .
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including fatal or life-threatening reactions, occurred in patients receiving AUCATZYL, including concurrently with CRS or after CRS resolution. Monitor for neurologic signs and symptoms after treatment with AUCATZYL. Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage neurologic toxicities. Provide supportive care and/or corticosteroids, as needed .
T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies .
Obecabtagene Autoleucel dosage
For autologous use only. For intravenous use only.
Strictly follow Administration instructions to minimize dosing errors .
The total recommended dose of AUCATZYL is 410 × 106 CD19 chimeric antigen receptor (CAR)-positive viable T cells supplied in three to five infusion bags. Bags are supplied in three color-coded bag configurations (10 × 106, 100 × 106, 300 × 106) for split dose administration.
CAR-positive T Cell Dose (Bag Configuration) | Color Code | Volume | Fully Infused
10 × 106 | Blue | 10 mL | No
100 × 106 | Orange | Variable | Yes
300 × 106 | Red | Variable | Yes
The treatment regimen consists of a split dose infusion to be administered on Day 1 and Day 10 (± 2 days), see Figure 1 and Figure 3.
The dosage regimen will be determined by the tumor burden assessed by bone marrow blast percentage from a sample obtained within 7 days prior to the start of lymphodepletion .
See the Release for Infusion certificate and Dose Schedule Planner for the actual cell counts and volumes to be infused and to select the appropriate dosage regimen .
Adverse Event | Severity 1. Based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening. | Actions Second Split Dose Day 10 (± 2 days)
Cytokine Release Syndrome following the first split dose . | Grade 2 | Consider postponing AUCATZYL infusion up to Day 21 to allow for the CRS to resolve to Grade ≤ 1.
Grade ≥ 3 | Discontinue treatment.
Immune Effector Cell-associated Neurotoxicity Syndrome following the first split dose . | Grade 1 | Consider postponing AUCATZYL infusion up to Day 21 to allow for the ICANS to completely resolve.
Grade ≥ 2 | Discontinue treatment.
Pulmonary or cardiac toxicities following the first split dose. | Grade ≥ 3 | Discontinue treatment.
Severe intercurrent infection at the time of AUCATZYL infusion . | Grade ≥ 3 | Consider postponing AUCATZYL infusion up to Day 21 until the severe intercurrent infection is considered controlled.
Requirement for supplementary oxygen. | Grade ≥ 3 | Consider postponing AUCATZYL treatment up to Day 21 to allow for the adverse reaction to resolve.
Other clinically relevant adverse reactions following the first split dose . | Grade ≥ 3 | Consider postponing AUCATZYL infusion up to Day 21 to allow for the adverse reaction to resolve.
AUCATZYL is for autologous use only. The patient's identity must match the patient identifiers on the AUCATZYL infusion bag. Do not infuse AUCATZYL if the information on the patient-specific label does not match the intended patient. …
How to take Obecabtagene Autoleucel — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Discuss the following with the patient:
Inform patients that there is a risk of manufacturing failure (4.5% [5/112 in clinical studies]). Therefore, a second manufacturing of AUCATZYL may be attempted, after a second leukapheresis collection.
Inform patients that additional therapy (other than lymphodepletion) may be necessary before AUCATZYL manufacturing is completed. This may increase the risk of adverse events during the pre-infusion period, which could delay or prevent the administration of AUCATZYL.
Advise patients to seek immediate attention if any of the following occur:
Cytokine Release Syndrome: Inform patients that symptoms may include fever, hypotension and hypoxia .
Neurologic Toxicity/ICANS: Inform patients that symptoms may include ICANS, headache, dizziness, anxiety, insomnia, delirium, tremor, and encephalopathy .
Prolonged Cytopenias: Inform patients that symptoms may include neutropenia, anemia, thrombocytopenia, or bleeding . …
Warnings & precautions
Do not take this medicine if: None.
Cytokine Release Syndrome (CRS) occurred following treatment with AUCATZYL. CRS was reported in 75% (75/100) of patients including Grade 3 CRS in 3% of patients.
The median time to onset of CRS was 8 days (range: 1 to 23 days) with a median duration of 5 days (range: 1 to 21 days). Sixty-eight percent of patients (51/75) experienced CRS after the first infusion, but prior to the second infusion of AUCATZYL with a median time to onset of 6 days (range: 1 to 10 days). Among patients with CRS, the most common manifestations of CRS included fever (100%), hypotension (35%) and hypoxia (19%) .
The primary treatment for CRS was tocilizumab (73%; 55/75), with patients also receiving corticosteroids (21%; 16/75).
Prior to administering AUCATZYL, ensure that healthcare providers have immediate access to medications and resuscitative equipment to manage CRS. During and following treatment with AUCATZYL, closely monitor patients for signs and symptoms of CRS daily for at least 7 days following each infusion. Continue to monitor patients for CRS for at least 2 weeks following each infusion with AUCATZYL . Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, immediately evaluate the patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Neurologic toxicities including Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), which were fatal or life-threatening, occurred following treatment with AUCATZYL. Neurologic toxicities were reported in 64% (64/100) of patients, including Grade ≥ 3 in 12% of patients.
The median time to onset of neurologic toxicities was 10 days (range: 1 to 246 days) with a median duration of 13 days (range: 1 to 904 days). …
Obecabtagene Autoleucel side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of AUCATZYL was evaluated in the FELIX study in which 100 patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) received AUCATZYL at a median dose of 410 × 106 CD19 CAR-positive viable T cells (range: 10 to 480 × 106 CD19 CAR-positive viable T cells with 90% of patients receiving the recommended dose of 410 × 106 ± 25%) .
The most common serious adverse reactions of any Grade (incidence ≥ 2%) included infections-pathogen unspecified, febrile neutropenia, ICANS, CRS, fever, bacterial infectious disorders, encephalopathy, fungal infections, hemorrhage, respiratory failure, hypotension, ascites, HLH/MAS, thrombosis and hypoxia.
Nine patients (9%) experienced fatal adverse reactions which included infections (sepsis, pneumonia, peritonitis), ascites, pulmonary embolism, acute respiratory distress syndrome, HLH/MAS and ICANS. Of the 9 patients, five patients who died from infections had pre-existing and ongoing neutropenia prior to receiving bridging therapy, lymphodepletion chemotherapy treatment and/or AUCATZYL.
Table 3 summarizes the adverse reactions (excluding laboratory abnormalities) that occurred in at least 10% of patients. …
About this medicine
AUCATZYL (obecabtagene autoleucel) is a CD19-directed genetically modified autologous Tcell immunotherapy comprised of the patient's T cells that are transduced with a lentiviral vector to express an anti-CD19 chimeric antigen receptor (CAR). The CAR is composed of a murine anti-CD19 single chain variable fragment (scFv) linked to 4-1BB and CD3-zeta co-stimulatory domains.
AUCATZYL is prepared from the patient's own peripheral blood mononuclear cells, which are collected via a standard leukapheresis procedure. The mononuclear cells are enriched for T cells, activated and transduced with a replication-incompetent lentiviral vector containing the CD19 CAR transgene. The transduced T cells are expanded in cell culture, washed, formulated into a suspension, and then cryopreserved. AUCATZYL is frozen in patient-specific infusion bag(s) and thawed prior to infusion . The product must pass a sterility test before it is released to the treatment center. The thawed product is a colorless to pale yellow, very opalescent suspension that is essentially free from visible foreign particles. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4fef6986-b988-45e4-8c20-b14f0ef1f538. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate